OncoMatch/Clinical Trials/NCT06274437
A Study of BND-35 in Participants With Advanced Solid Tumors
Is NCT06274437 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BND-35 and Nivolumab for cancer.
Treatment: BND-35 · Nivolumab · Cetuximab — This is an open-label, multicenter, dose escalation and dose optimization study designed to evaluate safety, tolerability and preliminary anti-tumor activity of BND-35 administered alone and in combination with nivolumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy. The study will be comprised of two parts - a dose escalation phase (Part 1) and a dose optimization (Part 2). Part 1 is comprised of three sub-parts: BND-35 administered alone (Sub-Part 1A), BND-35 administered in combination with nivolumab (Sub-Part 1B), and BND-35 administered in combination with cetuximab (Sub-Part 1C). Part 2 is composed of two sub-parts: a dose optimization part where up to two doses of BND-35 per indication are administered in combination with nivolumab or with cetuximab.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard approved therapy — refractory or not a candidate
refractory to or are not candidates for standard approved therapy
Cannot have received: immunoglobulin-like transcripts (ILT3)-targeting agents
Prior treatment with immunoglobulin-like transcripts (ILT3)-targeting agents
Lab requirements
Blood counts
Kidney function
Liver function
Participants must have adequate organ function as defined by laboratory tests
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify